<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01689259</url>
  </required_header>
  <id_info>
    <org_study_id>TNX-CY-F103</org_study_id>
    <nct_id>NCT01689259</nct_id>
  </id_info>
  <brief_title>Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized, Parallel-Design Study of the Comparative Pharmacokinetics and Safety of TNX-102 2.4 mg SL Tablets (With Phosphate) at 2.4 mg and 4.8 mg, TNX-102-A 2.4 mg SL Tablets (Without Phosphate) at 2.4 mg and Cyclobenzaprine 5 mg Oral Tablets in Healthy Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tonix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tonix Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Very low dose (VLD) cyclobenzaprine at bedtime has shown promise as a treatment for
      fibromyalgia, but the chemistry of cyclobenzaprine requires new formulation technology for
      bedtime use. The present trial is designed to assess the safety and tolerability of TNX-102
      2.4 mg SL Tablets (a new formulation of cyclobenzaprine designed to result in increased
      dosage precision and decreased potential for morning grogginess) at 2.4 mg and 4.8 mg and to
      compare the bio-availability of TNX-102 2.4 mg SL Tablets at 2.4 mg and 4.8 mg to that of
      TNX-102-A 2.4 mg SL Tablets (without phosphate) at 2.4 mg and cyclobenzaprine (5 mg tablets).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measured levels of cyclobenzaprine and norcyclobenzaprine in plasma and urine</measure>
    <time_frame>27 time points per period for blood assessment ; 3 pooled analyses in urine.</time_frame>
    <description>Blood samples will be taken per period: within 30 minutes pre-dose and 2, 3.5, 5, 10, 20, 30, and 45 minutes and 1, 2, 2.5, 3, 3.33, 3.67, 4, 4.33, 4.67, 5, 5.5, 6, 8, 12, 16, 24, 36, 48, and 72 hours post-dose. A single urine sample will be collected within 30 minutes pre-dose (one sample), and urine will be pooled from 0-24, 24-48 and 48-72 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of TNX-102 SL Tablets at 2.4 mg and 4.8 mg.</measure>
    <time_frame>Continuously until the end (day 4) of the study period + Telephone follow-up 7-13 days after dosing (total duration: about 1 month)</time_frame>
    <description>Every adverse events occurring during the study period will be reported.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>SL TNX-102 at 2.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x TNX-102 SL Tablets at 2.4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SL TNX-102 at 4.8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x TNX-102 SL Tablets at 2.4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SL TNX-102-A at 2.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x TNX-102-A (without phosphate) SL Tablet at 2.4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclobenzaprine tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 x 5 mg cyclobenzaprine oral tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL TNX-102 at 2.4 mg</intervention_name>
    <description>1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.</description>
    <arm_group_label>SL TNX-102 at 2.4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL TNX-102 at 4.8 mg</intervention_name>
    <description>2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.</description>
    <arm_group_label>SL TNX-102 at 4.8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL TNX-102-A at 2.4 mg</intervention_name>
    <description>1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.</description>
    <arm_group_label>SL TNX-102-A at 2.4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclobenzaprine tablets</intervention_name>
    <description>1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water</description>
    <arm_group_label>Cyclobenzaprine tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults

          -  Male or female

          -  Non-smoker

          -  18-65 years old

          -  BMI &gt; 18.5 and &lt; 30.0

          -  With medically acceptable form of contraception (female only)

          -  With signed informed consent

        Exclusion Criteria:

          -  Any clinically significant abnormality including ECG abnormalities or vital sign
             abnormalities (systolic blood pressure &lt; 90 or &gt; 140 mmHg,

          -  Diastolic blood pressure lower &lt; 50 or &gt; 90 mmHg, or heart rate &lt; 50 or &gt; 100 BPM)

          -  Any abnormal laboratory test (including positivity for Hep B, Hep C, HIV, and

          -  Hemoglobin &lt; 128 g/L (males) or &lt; 115 g/L (females) and hematocrit &lt; 0.37 L/L (males)
             or &lt; 0.32 L/L (females))

          -  History of alcohol or drug abuse or dependence within 1 year and/or positive drug,
             cotinine, or alcohol tests

          -  Use of any drug (within 30 days), supplement, or food (within 14 days) known to induce
             or inhibit hepatic drug metabolism prior to study medication

          -  Positive pregnancy test, breastfeeding or lactating

          -  Use of medication other than hormonal contraceptives or topical products, including
             OTC, natural health products, MAO inhibitors

          -  Participation in an investigational study within 30 days prior to dosing

          -  Donation of plasma (within 7 days), or donation or loss of blood of 50-499 mL (within
             30 days), or of &gt; 499 mL (within 56 days) prior to dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth M. Lederman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tonix Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey P. Kitrelle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tonix Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denis Audet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PharmaNet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PharmaNet, Inc.</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclobenzaprine</mesh_term>
    <mesh_term>Amitriptyline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

